{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:27:36Z","timestamp":1777332456996,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clinthera.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T13:19:40Z","timestamp":1710854380000},"page":"368-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-466X","authenticated-orcid":false,"given":"J.","family":"Chase Cole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha F.","family":"Benvie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marci","family":"DeLosSantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.02.007_bib0001","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0002","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0003","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0004","first-page":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.33963\/KP.a2021.0064","article-title":"Mavacamten\u2014a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy","volume":"79","author":"Pysz","year":"2021","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0006","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0007","series-title":"Camzyos (mavacamten) [prescribing information]","year":"2022"},{"issue":"10253","key":"10.1016\/j.clinthera.2024.02.007_bib0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0009","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0011","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0012","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0013","unstructured":"A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ClinicalTrials.gov website]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05582395. Accessed 4\/20\/23."},{"key":"10.1016\/j.clinthera.2024.02.007_bib0014","unstructured":"A Long-Term Safety Extension Study of Mavacamten in Adults Who have Completed MAVERICK-HCM or EXPLORER-HCM [ClinicalTrials.gov website]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03723655. Accessed 4\/20\/23."},{"key":"10.1016\/j.clinthera.2024.02.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0016","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clinthera.2021.11.006","article-title":"Projecting the long-term clinical value of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the United States: an assessment of net health benefit","volume":"44","author":"Desai","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2024.02.007_bib0018","unstructured":"Bristol-Myers Squibb Company. Camzyos REMS. Available at: https:\/\/www.Camzyosrems.Com. Accessed 4\/20\/23."},{"issue":"10272","key":"10.1016\/j.clinthera.2024.02.007_bib0019","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(20)32384-9","article-title":"Mavacamten for hypertrophic obstructive cardiomyopathy","volume":"397","author":"Quintana","year":"2021","journal-title":"Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T12:56:40Z","timestamp":1716296200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0149291824000626"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.02.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}